Drug Approval | June 17, 2024
Alembic announces USFDA final approval for Icatibant injection
This is the first peptide product approval from the USFDA received by Alembic Pharmaceuticals
This is the first peptide product approval from the USFDA received by Alembic Pharmaceuticals
There is an urgent need for more therapeutic treatment options for patients with painful osteoarthritis
Co-founder and previous CEO Lowry Curley becomes Chief Scientific Officer
Glenmark's current portfolio consists of 197 products authorized for distribution in the U.S. marketplace
Oligonucleotides are a unique modality with potential to address hard-to-treat diseases with high unmet need
The companies have initiated Phase 3 studies in patients with high-risk melanoma and non-small cell lung cancer
Merck shared updates on the company’s oncology pipeline and focused R&D approach
Facility in The Woodlands, Texas to produce critical starting material for cell and gene therapy, DNA/RNA-based, and recombinant protein therapeutics in Q1/2025
The Profit After Tax (PAT) for Q4 FY24 at Rs 36.40 crore, compared to Rs 38.23 crore in Q4 FY23
Sacubitril and Valsartan Tablets are indicated to reduce the risk of cardiovascular death
Subscribe To Our Newsletter & Stay Updated
